# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price targe...
Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from ...
Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shar...
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $30...
HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...
BTIG analyst Julian Harrison maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $46 t...